Product
UGN-301
1 clinical trial
5 indications
Indication
Bladder CancerIndication
NMIBCIndication
Bladder Carcinoma in SituIndication
Bladder Urothelial CarcinomaIndication
Urothelial Carcinoma RecurrentClinical trial
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBCStatus: Recruiting, Estimated PCD: 2025-12-01